Scott Wolchko: So on the last question with respect to clinical development in multiple myeloma. Obviously, there are patient costs associated with clinical development. We are — while we are not advancing 576 into dose expansion, we are in multiple myeloma. We are certainly expanding development in autoimmunity. And so in terms of changing cash burn, I don’t think we’re thinking about that as enhancing or saving or reducing on. We’re certainly investing in a lot. As it relates to B-cell depletion, I think keep in mind, with those 819 as well as 522, we are seeing very, very low levels of cells in many instances, and I’ll let Bob talk about it below lower limit of sort of detection. And so when we start getting into very, very low levels, you start to get into sort of can — you have a discussion about whether is there significant or not?
And I don’t believe, at least we think that we’re seeing different levels of depletion with 819 versus 522. I’ll let Bob comment on that. I will say just to be really clear, 522 — the 819 data set is over a much larger data set of patients. I think we used 23 patients with B-cell lymphoma for that data set. Some of those patients had relatively high B-cell counts going into the study. In fact, we noted that there were certain patients that had super physiological levels of B-cell counts that we were able to deplete with FT819. The 522 data set is, I think, only on two patients, and their B-cell counts generally were lower, on at baseline compared to the totality of the 819 patients. I think, I’ll let Bob talk on that. But I think generally speaking, what we’ve seen with respect to B-cell reconstitution from the SHED data as B-cell reconstitution actually can happen as, for instance, as early as the third or fourth week and can happen as late as four months.
But I’ll let Bob sort of finish up on that if I missed anything.
Bob Valamehr: No, I think you well covered it. When discussing 819, as Scott mentioned, there was a large number of patients, but it felt pretty much in line with showing very good B-cell depletion over the treatment cycle and B-cell recovery was seen in some of the patients. Now keep in mind, this is oncology. So what’s coming back up could be a lymphoma cell or something. So we’re in a much more aggressive stage than what SHED showed. But as Scott mentioned, what SHED showed is that B-cells do come back from 30 days to 180 days. So every patient treated all 15 and SHED data had by, I believe, day 180 full recovery of B-cells. So 819 is very much in line with what SHED showed. Now with 522, you’re bringing up a very good point.
And I think part of that has to do with the fact that it’s being combined with cytoxan. So this is kind of the one, two punch that we’re seeing. Again, two patients, I’m not going to sit here and speculate too much on it, but you are seeing the power of CAR plus hnCD16 in these settings. And I think both programs are — data has been so far very encouraging.
Ed Dulac: And Ethan, I’ll just pick up on Scott’s comments qualitatively, I agree. The mix of the business will change through the course of the year. But if you look at the first quarter, we had roughly $52 million, $53 million in GAAP operating expenses and about $37 million in cash burn, that’s been pretty consistent for the last couple of quarters. So even though we have one or two programs winding down, the hope is that now that we have first patient dose and we’re beginning to clear dose levels in certain programs, that’s going to tick up throughout the year. So I expect that those numbers I just quoted, we have $53 million on the GAAP operating expense and the $37 million, $38 million on the cash burn — effective cash burn for the quarter to remain fairly consistent.
I’m more than happy to invest behind these clinical programs. So if that picks up to, call it, circa $40 million on a cash burn basis, but we feel pretty good about where we are. Just the mix of the business will evolve, but that’s a pretty good number to work with for the rest of the year.
Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Scott Wolchko for any closing remarks.
Scott Wolchko: Thank you. Thank you for everyone today for all your good questions on the ASGCT data. I appreciate all the input and thought and speak to you soon. Thank you.
Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
